Details of the Drug Combinations

General Information of This Drug (ID: DMHQEA0)

Drug Name

Oltipraz DMHQEA0

Synonyms

CB-1400; Oltipraz (mucositis/radiation sickness/cancer); Oltipraz (mucositis/radiation sickness/cancer), Canopus Biopharma; Syntheticdithiolethione (oral, acute radiation syndrome/mucositis/cancer), Canopus

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Oltipraz + Marizomib	DCIKUAD	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02068339) Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis. U.S. National Institutes of Health.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.